Development of a novel nomogram for predicting delayed methotrexate excretion following high-dose methotrexate in adult patients with hematologic malignancies-Reference-Cited by-同舟云学术

Development of a novel nomogram for predicting delayed methotrexate excretion following high-dose methotrexate in adult patients with hematologic malignancies

Published:2024-06-21 Issue: Volume: Page:
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Ikeda Daisuke,Isezaki Tatsuya,Narita Kentaro,Yuyama Satoshi,Oura Mitsuaki,Uehara Atsushi,Tabata Rikako,Takeuchi Masami,Matsue Kosei

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00280-024-04687-z.pdf

Reference44 articles.

1. Jahnke K, Korfel A, Martus P, Weller M, Herrlinger U, Schmittel A et al (2005) High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. Ann Oncol 16(3):445–449. https://doi.org/10.1093/annonc/mdi075

2. Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD (2016) Preventing and managing toxicities of high-dose methotrexate. Oncologist 21(12):1471–1482. https://doi.org/10.1634/theoncologist.2015-0164

3. Relling MV, Fairclough D, Ayers D, Crom WR, Rodman JH, Pui CH et al (1994) Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol 12(8):1667–1672. https://doi.org/10.1200/JCO.1994.12.8.1667

4. Alsdorf WH, Karagiannis P, Langebrake C, Bokemeyer C, Frenzel C (2021) Standardized supportive care documentation improves Safety of High-Dose Methotrexate Treatment. Oncologist 26(2):e327–e32. https://doi.org/10.1002/onco.13603

5. May J, Carson KR, Butler S, Liu W, Bartlett NL, Wagner-Johnston ND (2014) High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective analysis. Leuk Lymphoma 55(6):1345–1349. https://doi.org/10.3109/10428194.2013.840780